(Q34391446)

English

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

phase II clinical trial

0 references

0 references

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michelle A Fanale

9

object named as

Michelle Fanale

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sattva S Neelapu

22

object named as

Sattva S Neelapu

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1

object named as

Jason R Westin

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

object named as

Luis E Fayad

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Nathan H Fowler

6

object named as

Nathan Fowler

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

5

object named as

Larry W Kwak

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Fredrick B Hagemeister

8

object named as

Fredrick Hagemeister

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jorge Romaguera

7

object named as

Jorge Romaguera

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

19

object named as

Tariq Muzzafar

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Felipe Samaniego

10

object named as

Felipe Samaniego

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Fuliang Chu

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Min Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lei Feng

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Veerabhadran Baladandayuthapani

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Zhiqiang Wang

13

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Wencai Ma

14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yanli Gao

15

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Michael Wallace

16

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Luis M Vence

17

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Laszlo Radvanyi

18

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Rinat Rotem-Yehudar

20

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

R Eric Davis

21

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

11 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

69-77

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Posttranscriptional control of T cell effector function by aerobic glycolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

The tumor microenvironment in follicular lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Pathogenesis of follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

T cell exhaustion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Effect of long-term storage in TRIzol on microarray-based gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Prevention of melanoma metastases in lungs of BAT treated and peptide immunized mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

BAT mAb induces lymphopoiesis in nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

The three Es of cancer immunoediting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

6 July 2018

Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Follicular lymphoma international prognostic index.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

27 October 2018

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922714

9 December 2018

Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970551-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970551-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970551-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amplified RNA synthesized from limited quantities of heterogeneous cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970551-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24332512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24332512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24332512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(13)70551-5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34391446&oldid=1960448323"